The price of innovation: new estimates of drug development costs
about
sameAs
A "reverse pharmacology" approach for developing an anti-malarial phytomedicine.Impact of alternative medical device approval processes on costs and healthComment: compulsory licensing of patented pharmaceutical inventions: evaluating the optionsEmerging drugs for uveitisThioridazine: resurrection as an antimicrobial agent?Old drugs--new usesA breakthrough in R&D; for neglected diseases: new ways to get the drugs we needEmerging role of bioinformatics tools and software in evolution of clinical researchChanging R&D; models in research-based pharmaceutical companiesRegenerative medicine: Current therapies and future directionsIntegrating lifestyle approaches into osteoarthritis careThe potential of anti-malarial compounds derived from African medicinal plants, part II: a pharmacological evaluation of non-alkaloids and non-terpenoidsAnalysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decadeiPSCs and small molecules: a reciprocal effort towards better approaches for drug discoveryThe answer is 17 years, what is the question: understanding time lags in translational researchMicrophysiological modeling of the reproductive tract: a fertile endeavorBiomarkers for osteoarthritis: current position and steps towards further validationA survey on the computational approaches to identify drug targets in the postgenomic eraThere should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacyTen years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinicSpinal cord injury neuroprotection and the promise of flexible adaptive clinical trialsMicroengineering in cardiovascular research: new developments and translational applications.Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imagingThree-dimensional cell culture systems and their applications in drug discovery and cell-based biosensorsR&D implementation in a department of laboratory medicine and pathology: a systematic review based on pharmaceutical companiesPREDICT: a method for inferring novel drug indications with application to personalized medicineQuantitative assessment of forward and backward second harmonic three dimensional images of collagen Type I matrix remodeling in a stimulated cellular environment.Novel methods and technologies for 21st-century clinical trials: a review.Attacking pathogens through their hostsVirtual screening of bioassay dataResearch for new drugs for elimination of onchocerciasis in AfricaU.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and LimitationsA New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical TrialsHow drugs are developed and approved by the FDA: current process and future directionsKey cost drivers of pharmaceutical clinical trials in the United StatesItraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growthIdentification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cellsUsing gene expression signatures to identify novel treatment strategies in gulf war illnessA comparative study on the cost of new antibiotics and drugs of other therapeutic categoriesMetabolomic profiling of drug responses in acute myeloid leukaemia cell lines
P2860
Q21034114-11653157-9B71-4F8F-9869-7EC5B27E3020Q24289148-1827DC01-3777-44C3-A54C-1C1B1846F039Q24626302-2D54D4B0-4EA3-41E0-B759-4413D8EE9F34Q24630848-ECA9FEAE-9870-471C-B286-951FC28B6298Q24650111-1D109E5E-80CF-4037-801E-369C866408CCQ24650207-8B284507-6276-41BB-9A01-07E98EF99C81Q24810470-3B1B012B-03ED-49A5-B08C-F418EF694CB5Q26741869-6E8DE45C-DF1E-4BF5-8681-270554301064Q26749511-47B4F2FF-8ED5-4071-A1BC-62D65D1304A9Q26776380-F3077D17-246A-4B2E-9D5C-257A1FC40666Q26781937-CAB4C454-F38E-46FD-82C7-6B83673EF7F9Q26824879-A38310DE-091C-498D-8143-AED4FB98ACB7Q26849409-101EE5FE-BE47-4B6B-80DC-C532785CDE92Q26865055-2C4323B1-1E55-444B-BA96-9387EB25462EQ26967565-434D3847-532B-458D-92E2-C40CA389DB6CQ26991591-5345B46E-0130-4157-BA4F-1D4E675AAB31Q27002552-B74495F9-7FE6-46BC-B6A4-7D101EB43086Q27003870-1D31E09F-5F90-421C-B124-5463FCC37E3BQ27005826-59B4F9B8-348E-4B4D-9137-3D081E0B829CQ27007413-1D483127-7249-4599-AB2D-278A94A880B5Q27008862-09BD9DAE-1660-44EF-8083-5186E41A5D86Q27015747-D17E3268-4230-487C-806D-A09C15C64EDBQ27023605-BDA575B4-F65D-4F91-AA11-B91D430DD24CQ27023623-F0210E4C-AA30-4D83-AEA5-4552A6486BB1Q27026296-62BC5477-EADC-453C-8660-C7B8D8FDBD41Q27137071-523516C6-1D80-4553-9F1C-7A1A2FB940FDQ27309032-6472A6C9-60A3-4E84-B8DF-FAACCCC3DF0CQ27345820-3F7B712A-CA54-46B5-928B-DB86C69A1947Q27473132-247DAC79-75FD-4A12-83B7-5D5D6C77F580Q27998660-8D047057-9B5E-4D4F-8FED-CA8AFE666DC6Q28066402-B1D6F402-1F81-40FD-B0C3-0280541F29A5Q28072494-4EF6CAE1-82BA-4428-846D-467C8DDEFB4EQ28084983-23701F9D-8EBE-4427-A442-0C34EA71A3ABQ28239492-C3483204-89EF-438A-9458-05C8190CEC58Q28273573-E32A2B8D-F007-409D-9C8A-871ADF54D006Q28279473-6ADAB1ED-F701-46F1-9E5D-BB2F4A62C446Q28284818-6B00A393-927D-4810-B271-B99F478C6D6FQ28397964-2F0FBD20-F17C-46B8-8157-33D8F5FEF499Q28469093-0E246D91-94BC-460A-AECA-4468B56C3170Q28474545-8665DC4E-7D9B-4E83-8177-457AD467FEA4
P2860
The price of innovation: new estimates of drug development costs
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The price of innovation: new estimates of drug development costs
@ast
The price of innovation: new estimates of drug development costs
@en
The price of innovation: new estimates of drug development costs
@nl
type
label
The price of innovation: new estimates of drug development costs
@ast
The price of innovation: new estimates of drug development costs
@en
The price of innovation: new estimates of drug development costs
@nl
prefLabel
The price of innovation: new estimates of drug development costs
@ast
The price of innovation: new estimates of drug development costs
@en
The price of innovation: new estimates of drug development costs
@nl
P2093
P3181
P1476
The price of innovation: new estimates of drug development costs
@en
P2093
Henry G Grabowski
Joseph A DiMasi
Ronald W Hansen
P304
P3181
P356
10.1016/S0167-6296(02)00126-1
P407
P577
2003-03-01T00:00:00Z